JOURNAL ARTICLE
REVIEW
Add like
Add dislike
Add to saved papers

Anovulation and monophasic cycles.

Normal pubertal development is often considered complete when the adolescent experiences her first menstrual period. However, sexual maturity is not attained until the onset of regular ovulatory cycles, which may take a number of months to years to accomplish. This maturation process is orchestrated by a neuroendocrine cascade and modified by autocrine and paracrine events in the ovary. The control of these complex relationships takes time and could not be expected to be fully functional with menarche. During the first menstrual months, the hypothalamic-pituitary-ovarian axis is immature, resulting in the secretion of only estrogens from the developing follicles; positive feedback to trigger ovulation develops later. Consequently, estrogen secretion is variable and unopposed by progesterone, which would normally be produced in ovulatory cycles. Estrogen-only primed endometrium often leads to irregular menstrual cycles with variable flow. Surprisingly, most adolescents do well and have few complaints in spite of these anovulatory cycles. If an abnormality is experienced with the menstrual cycle, once understood physiologically, it can be managed simply, by watchful expectancy or intermittent progestin therapy. Occasionally, sever menstrual bleeding is encountered, and in a proportion of these patients a thorough assessment will delineate an underlying medical problem that needs to be addressed. The management of these patients requires ingenuity from the pediatric reproductive endocrinologist and aggressive hormonal manipulation. Most patients do well, but some require long-term continuing care.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.
Urinary Tract Infections: Core Curriculum 2024.American Journal of Kidney Diseases 2023 October 31

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app